Selective Killing of Normal and Neoplastic Human B Cells with Anti-CD 19- and Anti-CD22-Ricin A Chain Immunotoxins

R. D. May, E. S. Vitetta, G. Moldenhauer, B. Dorken

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Monoclonal antibodies directed against two human B cell-restricted antigens, CD19 and CD22, were conjugated to highly purified ricin A chain. These A chain immunotoxins (A-IT) were specifically cytotoxic to Daudi cells and normal human peripheral blood B cells in vitro. The concentration required for 50% inhibition of protein synthesis (IC50) in these cells ranged from 7.5 x 10-10 M to 4.2 x 10-9 M. The specific toxicities of these A-ITs for Daudi cells were augmented 2-to 6-fold in the presence of 20mM NH4Cl. These studies demonstrate that A-ITs specific for CD19 and CD22 may be useful in the clinical treatment of B cell malignancies.

Original languageEnglish (US)
Pages (from-to)261-272
Number of pages12
JournalCancer Drug Delivery
Volume3
Issue number4
DOIs
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Selective Killing of Normal and Neoplastic Human B Cells with Anti-CD 19- and Anti-CD22-Ricin A Chain Immunotoxins'. Together they form a unique fingerprint.

  • Cite this